FDA批准Bristol Myers Squibb的新注射器 Opdivo Qvantig用于治疗固态肿瘤。 FDA approves Bristol Myers Squibb's new injectable Opdivo Qvantig for treating solid tumors.

食品药品管理局批准了Bristol Myers Squibb的新注射形式Opdivo,叫做Opdivo Qvantig,用于治疗各种固态肿瘤。 The FDA has approved Bristol Myers Squibb's new injectable form of Opdivo, called Opdivo Qvantig, for treating various solid tumors. 被批准用作独立治疗、维持疗法或与化疗结合使用的注射版本旨在为病人提供与IV表相比更为方便的选项,其效果和安全特征类似。 Approved for use as a standalone treatment, maintenance therapy, or in combination with chemotherapy, the injectable version aims to offer patients a more convenient option compared to the IV form, with similar efficacy and safety profiles. 预计将于1月初上市,价格与IV版本相似,每注液约为7635美元至15269美元. Expected to be available in early January, it will be priced similarly to the IV version, which costs around $7,635 to $15,269 per infusion.